Market Size (2016)
2016
$661.38M
Vertical: HealthcareBase Year: 201911 Sections
Market Size (2016)
2016
$661.38M
Projected (2027)
2027
$3.39B
CAGR (2016–2027)
16.0%
16.0%Key Players
109+
Metagenomic sequencing is a modern genomics technique that helps in the analysis of microbial DNA from various environmental communities. Metagenomics sequencing allows researchers to analyze genes in any given sample. This method enables access to bacterial diversity and identifies the presence of microbes in various environments.
Factors that drive the market growth are the wide range of applications of metagenomics in various fields, rising government funding and initiatives for growth of sequencing techniques, and declining cost of sequencing. However, unfavorable regulatory policies are hampering the growth of the market.
The Metagenomic Sequencing Market market is projected to grow at a CAGR of 16.0% from 2016 to 2027.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansScope of the Study
The scope of the global metagenomic sequencing market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on product & service, application, technology, and region.
Research Objective
To provide a comprehensive analysis of the global metagenomic sequencing market and its sub-segments, thereby providing a detailed structure of the industry To provide detailed insights into factors driving and restraining the growth of the global metagenomic sequencing marketTo estimate the market size of the global metagenomic sequencing market where 2017 to 2018 would be the historic period, 2019 shall be the base year, and 2020 to 2027 will be the forecast period for the studyTo provide region-wise market value analysis for various segments of the global metagenomic sequencing marketTo provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this marketTo provide a distribution chain analysis/value chain for the global metagenomic sequencing market
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2019
Historical Period
2016 – 2019
Forecast Period
2019 – 2027
Primary Interviews
150+
Historical data (2016–2019) and forecast period (2019–2027)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants in the global metagenomic sequencing market is medium. Any company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. The market is also characterized by a high degree of brand loyalty, where establishing a brand name is difficult for newcomers. The rise in the demand for metagenomic sequencing technology owing to its potential growth in the coming future is expected to attract the currently established and other manufacturers to focus more on this segment. Furthermore, the cost involved in research and development (R&D) is comparatively high, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global metagenomic sequencing market are raw material suppliers. There are various suppliers present in the global metagenomic sequencing market. At present, there are a number of suppliers present in the market owing to the high demand, increasing government support, and the availability of huge opportunities for the development of the market. The market is dominated by a few existing significant companies, and they hold the major share in the global market and have the capability of fluctuating the costs of the products. However, the switching cost of these suppliers is low to medium because suppliers tend to enter into long-term associations, partnerships, and deals with the other product manufacturing companies. Therefore, the overall bargaining power of suppliers in the global advanced wound therapy devices market is medium.
Threat of Substitutes
The threat of substitutes in the global metagenomic sequencing market is medium, as it is still an upcoming technology. Although there are no direct threats, other genome sequencing technologies take up a significant share.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global metagenomic sequencing market. The presence of buyers in the market is growing due to the increasing awareness about the different products, along with the rising prevalence of cancer. Additionally, the presence of providers is also increasing, which makes the bargaining power of buyers moderate due to the low switching costs.
Intensity of Rivalry
The degree of competition in the global metagenomic sequencing market is high. Companies involved in the metagenomic sequencing market are trying to introduce more advanced products, for differentiating their product from their rivals. Moreover, manufacturers also focus on the enhanced safety and quality of the products to increase the demand for these products in developed countries and developing regions. To overcome the competition, players are engaged in partnering with established organizations and welcoming tie-ups.
Market estimates by geography (2027)
InsightAmericas leads with $2.08B by 2027.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2019 | 2027 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $148.17M | $354.95M | $779.82M | 16.3% | 23% |
| Asia Pacific | $82.84M | $196.91M | $429.80M | 16.1% | 13% |
| Middle East and Africa | $38.48M | $68.09M | $105.95M | 9.6% | 3% |
| Americas | $391.89M | $942.76M | $2.08B | 16.4% | 61% |
| Total | $661.38M | $1.56B | $3.39B | 16.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$3.39B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Reagents & Consumables | $2.25B | 16.0% | 40% |
| Services | $534.71M | 16.0% | 89% |
| Instruments | $452.82M | 16.0% | 89% |
| Analysis and Data Interpretation Solutions | $161.22M | 16.0% | 85% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Metagenomic Sequencing Market covering market dynamics, competitive landscape, and strategic outlook.
The Metagenomic Sequencing Market market is projected to reach $3.39B by 2027, growing at 16.0% CAGR. The Reagents & Consumables segment holds the largest share.
Metagenomic sequencing is a modern genomics technique that helps in the analysis of microbial DNA from various environmental communities. Metagenomics sequencing allows researchers to analyze genes in any given sample. This method enables the access of bacterial diversity and identifies the presence of microbes in various environments.
Factors that drive the market growth are the wide range of applications of metagenomics in various fields, rising government funding and initiatives for growth of sequencing techniques, and declining cost of sequencing. However, unfavorable regulatory policies are hampering the growth of the market.
Genomics analyzes the fiction and structure of genomes. Genomics uses DNA sequencing to decode and analyze genomes. Gene sequencing is a useful tool for cancer diagnostic and various other infectious diseases. Recent medicine trends and collaborations of the healthcare industry with regulatory authorities for genome sequencing would support and expand genomic sequencing practices around the globe. Moreover, public and private funding for the development of genomic research is also likely to support market growth. This favorable scenario creates an opportunity for the metagenomic sequencing market.
Some of the major genome mapping and funding programs supporting the market growth include,
In 2016, the government of France announced a program, namely, the “Medecine Genomique 2025”. This program aims to open 12 genome sequencing centers in France.In 2017, XIFIN Inc. launched the next-generation sequencing module. This module delivers advanced workflow functionality for laboratory sequencing operations and precision medicine.National Human Genome Research Institute (NHGRI) in 2019, awarded USD 2.5 million to Washington University in St. Louis (WashU), University of California, Santa Cruz (UCSC), and the European Bioinformatics Institute (EBI), which will coordinate with the National Center for Biotechnology Information, to form the WashU-UCSC-EBI Human Genome Reference Center. This center aims to provide a next-generation reference sequence of the human genome as a resource for the scientific community and support interactions within the genomics community.In 2018, All of Us Research Program, a part of the National Institutes of Health, awarded funds over USD 28.6 million to establish three genome centers in the US. These centers will produce genome data for researchers and program’s precision medicine research platform, a national resource to support studies on a variety of important health questions.
Many companies face challenges in storing the sequencing test data. The genome sequencing technology produces a large volume of sequencing data during the research activity. Large data creates storage challenges for the operator. The cloud-based technology helps resolve the storage issue in sequencing data. Cloud-based solutions are used for data storage, effective data management, and analysis of the large volume of data. This advantage helps companies to focus on cloud-based technology. Cloud-based solutions create an opportunity for companies to develop and capture the maximum share in the metagenomic sequencing market. Recently in January 2018, Illumina launched BaseSpace Sequence in China. It is a cloud-based solution used for genomic data storage and analysis of samples.
This cloud-based technology acts as an opportunity for the growth of the metagenomic sequencing market
Reimbursement policies for genome sequencing testing vary widely among private and public insurers. The availability of funding and reimbursement is only for the FDA approved NGS tests, which are performed in laboratories. The reimbursement is not applicable for genome sequencing tests, which are not approved by the FDA. Recently, the Centers for Medicare and Medicaid Services finalized the National Coverage Determination to cover only FDA approved diagnostic laboratory tests used for genome sequencing for patients who have advanced cancer.
This unfavorable reimbursement policy impacts on implementation and adoption of genome sequencing testing performed in laboratories. The testing cost is a major barrier to the implementation of genome sequencing testing. Due to the high cost of genome sequencing testing, it is still not affordable for patients. These unfavorable regulatory policies towards genome sequencing tests would restrain the metagenomic sequencing market during the forecast period.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Metagenomic Sequencing Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Novogene Corporation
Company Headquarters: Beijing, China Founded: 2011 Workforce: ~2,600 Company Working: Novogene Corporation (Novogene) is a leading provider of genomic services and solutions with cutting edge bioinformatics expertise. The company focuses on genome research and bioinformatics development. It offers genomic solutions in which the sequencing and assembly of whole genomes for variation detection, population evolution, genetic map, and functional gene mapping. The company owns 27 NGS-related patents, as well as the publishing of over 4,920 customer research papers in publications such as Nature and Science. Its genomic sequencing labs are present in the US, the UK, and China. Additionally, Novogene has a genomic center in Singapore in partnership with AIGbiotech, a biotechnology company in Singapore. It has advanced NGS capacity and serves 4,000 customers worldwide.
GENEWIZ
Company Headquarters: New Jersey, US Founded: 1999 Workforce: ~500-1000 Company Working: GENEWIZ is a global leader in the research and development of genomic services. It is committed to performing research activities through fast, reliable delivery of quality results, competitive prices, excellent project management, and easy access to expert technical support. The company offers a variety of genomic services, including Sanger DNA sequencing, gene synthesis, molecular biology, high throughput/next-generation sequencing, bioinformatics, and GLP regulatory services. It has a growing network of genomic laboratories globally, including the US, the UK, and China. It provides solutions and services compliant with the Good Laboratory Practice (GLP), Clinical Laboratory Improvement Amendments (CLIA) regulations, and College of American Pathologist (CAP) standards. It won different industry awards, including the Frost & Sullivan 2016 North America Life Science Research Services Company of the Year Award.
BGI
Company Headquarters: Shenzhen, China Founded: 1999 Workforce: ~3150 Company Working: BGI is a publicly listed commercial genomics company. It is one of the leading life science and genomics organizations. The company has world-leading bio-informatics research and development, large scale computing infrastructure for data output and storage, and proprietary sequencing platforms. It operates through molecular genetics, sequencing services, mass spec, and pharma solutions. It offers a wide range of integrated genomic and proteomic services and solutions for medical institutions, research institutions, and other public and private partners. BGI offers its genomics and proteomics services in research areas, such as cancer, metagenomics, drug discovery, reproductive health, and biomarker discovery. It has a presence in more than 100 countries and regions around the world and has a large network of service laboratories in China, Hong Kong, the US, and Europe.
Illumina Inc.
Company Headquarters: California, US Founded: 1998 Workforce: 7,700+ Company Working: Illumina, Inc. (Illumina) operates in genomics, an industry at the intersection of biology and technology. Illumina focuses on innovating and improving human health by offering a wide range of innovative products. Its initial products have enabled researchers to explore DNA at an entirely new scale and helped them create the first map of gene variations associated with health, disease, and drug response. It serves customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. It has a presence in major regions such as North America, Europe, and Asia.
Integragen SA
Company Headquarters: Évry, France Founded: 2000 Company Working: Integragen SA is a leading provider of advanced genomic and bioinformatic services to researchers. It develops and commercializes molecular diagnostic tests for oncology. The company has expertise with the latest technology platforms and the newest bioinformatics tools. It has partnerships with leading academic centers such as Gustave Roussy and Institute Pasteur to help operate sequencing platforms at their institutions.
Qiagen
Company Headquarters: Germany, Europe Founded: 1984 Workforce: 5,000 Company Working: Qiagen is a healthcare company that deals in sample and assay technologies for molecular diagnostics. The company operates through more than 35 offices spread in over 25 countries. It serves more than 500,000 customers across the globe. Its product portfolio spans through a full range of molecular testing applications. Qiagen’s products are used for extraction, purification, and stabilization of DNA, RNA, and protein from various biological samples. It has over 500 core products in its portfolio. The company is listed on the New York Stock and Frankfurt Prime Standard exchanges. It offers its products in various areas such as discovery & translational research, diagnostics & clinical research, next-generation sequencing, and instruments & automation.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Metagenomic Sequencing Market